3 assets in Micropapillary Variant Infiltrating Bladder Urothelial Carcinoma

Therapeutic assets addressing Micropapillary Variant Infiltrating Bladder Urothelial Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cabozantinib Micropapillary Variant Infiltrating Bladder Urothelial Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Micropapillary Variant Infiltrating Bladder Urothelial Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Micropapillary Variant Infiltrating Bladder Urothelial Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)